There are no standard chemotherapeutic options for patients with squamous cell anal carcinoma, relapsing and progressing on palliative cisplatin-based regimens. Similarly to other malignant conditions, monoclonal antibodies directed against the epidermal growth factor receptor may represent an attractive therapeutic strategy. Here we describe a patient who, based on molecular profile, benefited from the combination of irinotecan and cetuximab.
NigroN.D., SeydelH.G., ConsidineB., VaitkeviciusV.K., LeichmanL., KinzieJ.J.: Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer, 51: 1826–1829, 1983.
2.
JaiyesimiI.A., PazdurR.: Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. Am J Clin Oncol, 16: 536–540, 2003.
3.
EvansT.R., MansiJ.L., GleesJ.P., DalgleishA.G., KnightM.J.: Response of metastatic anal carcinoma to single agent carboplatin. Clin Oncol, 5: 57–58, 1993.
4.
FisherW.B., HerbstK.D., SimsJ.E., CritchfieldC.F.: Metastatic cloacogenic carcinoma of the anus: sequential responses to adriamycin and cis-dichlorodiammineplatinum(II). Cancer Treat Rep, 62: 91–97, 1978.
5.
GrifaichiF., PadovaniA., RomeoF., TrincaC., MoscettiL., CortesiE.: Response of metastatic epidermoid anal cancer to single agent irinotecan: a case report. Tumori, 87: 58–59, 2001.
6.
AlvarezG., PerryA., TanB.R., WangH.L.: Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Pathol, 19: 942–949, 2006.
7.
Van CutsemE., KöhneC.H., HitreE., ZaluskiJ., Chang ChienC.R., MakhsonA., D'HaensG., PintérT., LimR., BodokyG., RohJ.K., FolprechtG., RuffP., StrohC., TejparS., SchlichtingM., NippgenJ., RougierP.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med, 360: 1408–1417, 2009.
8.
LorenzenS., SchusterT., PorschenR., Al-BatranS.E., HofheinzR., Thuss-PatienceP., MoehlerP., GrabowskiP., ArnoldD., GretenT., MüllerL., RöthlingN., PeschelC., LangerR., LordickF.: Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol, 20: 1667–1673, 2009.
9.
VermorkenJ.B., TrigoJ., HittR., KoralewskiP., Diaz-RubioE., RollandF., KnechtR., AmellalN., SchuelerA., BaselgaJ.: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol, 16: 2171–2177, 2007.
10.
PhanL.K., HoffP.M.: Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis Colon Rectum, 50: 395–398, 2007.
11.
SobreroA.F., MaurelJ., FehrenbacherL., ScheithauerW., AbubakrY.A., LutzM.P., Vega-VillegasM.E., EngC., SteinhauerE.U., PrausovaJ., LenzH.J., BorgC., MiddletonG., KröningH., LuppiG., KiskerO., ZubelA., LangerC., KopitJ., BurrisH.A.: 3rd EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol, 26: 2311–2319, 2008.
